Rhythm Pharmaceuticals wins first-ever approval for acquired hypothalamic obesity; FDA approves Lilly's oral GLP-1 Foundayo
April 1st, 2026: FDA approves Eli Lilly's Foundayo, first convenient GLP-1 pill for weight lossNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
For the first time, patients with acquired hypothalamic obesity have an FDA-approved treatment. On March 19, 2026, the FDA approved Imcivree (setmelanotide), which targets this rare condition affecting roughly 10,000 Americans whose hypothalamic damage from brain tumor surgery makes diet and exercise ineffective.
In clinical trials, Imcivree patients lost 18.4% more body mass than those on placebo over one year. Two weeks later, on April 1, the FDA approved Eli Lilly's Foundayo (orforglipron), the first GLP-1 pill taken without food restrictions, achieving 12.4% weight loss.
Imcivree works through a completely different mechanism, directly activating melanocortin-4 receptors in the brain to restore satiety signaling that hypothalamic damage destroyed. Mainstream drugs like Foundayo, Wegovy, and Zepbound target the tens of millions with common obesity through gut-hormone pathways. Obesity treatment now addresses both rare hypothalamic cases and common obesity.
Why it matters
The first approved drug for acquired hypothalamic obesity becomes available, while common obesity gains expanded pharmacotherapy choices.
No questions yet — be the first to ask.
White measuring tape with a white pills, white vitamin on a yellow background. Diet. Slimming. Obesity. Place for an inscription. Weight loss marathon. Advertising. Top view. The close plan.
Pink pills arranged in a prohibition symbol in sunlight, symbolizing drug restrictions.
Young South African woman taking insulin for Type 1 diabetes with an insulin injection pen.
How FDA Approved Medications Are Changing Obesity ...
MD Newsline
FDA approves weight loss drug Zepbound, joining Ozempic ...
CBS News
FDA approves diabetes drug to treat obesity
ABC News
Images from Openverse under Creative Commons licenses. Videos from YouTube.
Curated perspectives — historical figures and your fellow readers.
Fictional AI pastiche — not real quote.
"How singular that we have at last found a pill to convince the brain it is satisfied — a sensation the rest of us have been chasing in gin and bad marriages for centuries."
Exploring all sides of a story is often best achieved with Play.
Your progress in this debate will be lost.
Choose one persona for each side of the debate
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Make your prediction before the referee scores
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
A Boston-based rare disease company focused on obesity caused by dysfunction in the melanocortin-4 receptor (MC4R) signaling pathway.
The federal agency responsible for evaluating and approving pharmaceutical drugs for safety and efficacy in the United States.
A global pharmaceutical leader advancing oral formulations of incretin therapies for obesity and diabetes.
Danish company dominating obesity treatment with semaglutide-based therapies.
September 1997 April 2026
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for obesity that can be taken anytime without food or water restrictions. Phase 3 trials showed 12.4% average weight loss over 72 weeks. Priced at $149/month self-pay, shipping starts April 6.
Rhythm Pharmaceuticals receives FDA approval for the first and only treatment for acquired hypothalamic obesity in adults and children aged 4 and older. The approval was based on the 142-patient TRANSCEND trial showing an 18.4% placebo-adjusted BMI reduction.
The FDA approves Wegovy 7.2 mg, a higher-dose version of the semaglutide injection, achieving 20.7% weight loss—underscoring the rapid expansion of obesity treatment options.
FDA approves oral semaglutide 25 mg (oral Wegovy), eliminating the need for injections. Novo Nordisk prices it at $149 per month.
The FDA accepts Rhythm's supplemental new drug application for review, initially setting a decision deadline of December 2025.
Rhythm Pharmaceuticals announces that setmelanotide achieved a 19.8% placebo-adjusted BMI reduction in 120 patients with acquired hypothalamic obesity over 52 weeks.
Based on the SELECT trial showing a 20% reduction in major cardiovascular events, Wegovy becomes the first drug approved specifically to reduce heart risk in overweight and obese patients.
FDA approves tirzepatide injection, a dual GIP/GLP-1 receptor agonist, for chronic weight management. At its highest dose, patients lost an average of 48 pounds.
FDA approves Imcivree for Bardet-Biedl syndrome, a rare genetic condition affecting an estimated 1,500 to 2,500 Americans. First approved treatment for the condition.
FDA approves semaglutide 2.4 mg injection for chronic weight management, achieving roughly 15% weight loss—approaching surgical results with a weekly injection.
FDA approves setmelanotide for obesity caused by POMC, PCSK1, or LEPR gene deficiencies—conditions affecting only hundreds of patients worldwide.
Belviq (lorcaserin) becomes the first new obesity drug approved since 1999, followed weeks later by Qsymia. Belviq would later be withdrawn in 2020 due to cancer signal.
Fenfluramine pulled from market after causing valvular heart disease. Manufacturer eventually paid over $13 billion in damages. Begins a 13-year freeze on new obesity drug approvals.
3 moments from history that rhyme with this story — and how they unfolded.
Fenfluramine, half of the wildly popular fen-phen diet drug combination that generated 18 million monthly prescriptions in 1996, was pulled from the market after causing heart valve damage. Manufacturer American Home Products (later Wyeth) paid over $13 billion in legal damages. Surveys later found 31% of healthcare providers said they would never prescribe obesity medication again.
The FDA approved no new obesity drugs for 13 years, from 1999 to 2012. Obesity was treated almost exclusively through lifestyle counseling and bariatric surgery.
The scandal created deep regulatory caution and physician reluctance around obesity pharmacotherapy that took two decades and the GLP-1 revolution to overcome.
The fen-phen disaster explains why obesity treatment languished for so long—and why each new approval, especially for vulnerable populations like children with hypothalamic damage, carries heightened scrutiny for safety. Imcivree's clean safety profile in the TRANSCEND trial matters against this backdrop.
The FDA approved Ceredase (alglucerase) for Gaucher disease, an ultra-rare genetic condition affecting roughly 6,000 Americans. Developed by Genzyme, it was one of the first successful rare disease therapies and established the model of orphan drug development—targeting small patient populations with high unmet need at premium prices.
Genzyme built a profitable rare disease business around a single enzyme replacement product, demonstrating that rare conditions could sustain pharmaceutical companies.
The orphan drug model became a standard pharmaceutical strategy: prove efficacy in a rare, well-defined population, then expand to adjacent conditions sharing the same biological pathway.
Rhythm Pharmaceuticals is following the same playbook Genzyme pioneered: start with ultra-rare genetic deficiencies (POMC, PCSK1, LEPR), expand to a broader rare syndrome (Bardet-Biedl), then move into a larger acquired condition (hypothalamic obesity) that shares the same MC4R pathway disruption. The question is how far the pathway-based expansion can reach.
The FDA approved imatinib, a targeted therapy that specifically blocked the BCR-ABL protein driving chronic myeloid leukemia (CML). Developed by Novartis, it transformed CML from a near-certain death sentence into a manageable chronic condition, achieving complete remission in most patients. It was approved in just 2.5 months—one of the fastest reviews in FDA history.
Five-year survival rates for CML jumped from roughly 30% to over 90%. Imatinib became one of the best-selling cancer drugs in history.
Imatinib proved that drugs targeting a specific molecular mechanism could be transformative, launching the era of precision medicine in oncology.
Like imatinib targeting BCR-ABL in leukemia, setmelanotide targets a specific disrupted signaling pathway (MC4R) rather than treating symptoms broadly. Both drugs work best when the underlying biological defect is well understood and directly addressable—and both demonstrate that targeting the right mechanism can produce results in conditions previously considered untreatable.